{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:59:09Z","timestamp":1785895149501,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1106,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41379-019-0358-x","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T14:11:06Z","timestamp":1567433466000},"page":"118-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy"],"prefix":"10.1016","volume":"33","author":[{"given":"Douglas","family":"Rottmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia L.","family":"Snir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-019-0358-x_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2014.10.013","article-title":"Rare uterine cancer: carcinosarcomas. Review from histology to treatment","volume":"94","author":"Artioli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1038\/s41379-019-0358-x_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ygyno.2017.02.001","article-title":"Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma","volume":"145","author":"Matsuo","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/GRF.0b013e31821ac635","article-title":"Uterine carcinosarcoma","volume":"54","author":"El-Nashar","year":"2011","journal-title":"Clin Obstet Gynecol"},{"key":"10.1038\/s41379-019-0358-x_bib4","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/IGC.0000000000000228","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma","volume":"24","author":"Berton-Rigaud","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/s41379-019-0358-x_bib5","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/IGC.0b013e3181dc8292","article-title":"Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes","volume":"20","author":"Garg","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/s41379-019-0358-x_bib6","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0b013e3181161ba3","article-title":"Prognostic features of surgical stage I uterine carcinosarcoma","volume":"31","author":"Ferguson","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-019-0358-x_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2013.07.097","article-title":"Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis","volume":"131","author":"Rauh-Hain","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2011.08.020","article-title":"The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma","volume":"123","author":"Tanner","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ygyno.2004.11.022","article-title":"Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","article-title":"Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study","volume":"25","author":"Homesley","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib11","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1200\/JCO.2019.37.15_suppl.5500","article-title":"A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: an NRG Oncology trial","volume":"37","author":"Powell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0358-x_bib13","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin\u2013paclitaxel versus carboplatin\u2013paclitaxel\u2013trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib14","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1158\/1078-0432.CCR-16-2862","article-title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/Neu expression","volume":"23","author":"Menderes","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-019-0358-x_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-014-9688-8","article-title":"T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2","volume":"32","author":"Nicoletti","year":"2015","journal-title":"Clin Exp Metastas"},{"key":"10.1038\/s41379-019-0358-x_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2015.08.002","article-title":"Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo","volume":"139","author":"Schwab","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-019-0358-x_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-019-0358-x_bib19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ygyno.2005.09.017","article-title":"Clinical features and outcomes of uterine and ovarian carcinosarcoma","volume":"100","author":"Jonson","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2008.05.016","article-title":"Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis","volume":"111","author":"Nemani","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib21","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.20256","article-title":"Carcinosarcoma of the ovary: 19 years of prospective data from a single center","volume":"100","author":"Brown","year":"2004","journal-title":"Cancer"},{"key":"10.1038\/s41379-019-0358-x_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<821::AID-IJC19>3.0.CO;2-B","article-title":"Uterine carcinosarcoma is derived from a single stem cell: an in vitro study","volume":"72","author":"Gorai","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1038\/s41379-019-0358-x_bib23","first-page":"5379","article-title":"Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors","volume":"57","author":"Wada","year":"1997","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-019-0358-x_bib24","first-page":"114","article-title":"Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity","volume":"60","author":"Fujii","year":"2000","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-019-0358-x_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/ijgc-00009577-200211000-00001","article-title":"Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas","volume":"12","author":"McCluggage","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/s41379-019-0358-x_bib26","first-page":"309","article-title":"Novel targeted therapies in ovarian and uterine carcinosarcomas","volume":"25","author":"Han","year":"2018","journal-title":"Discov Med"},{"key":"10.1038\/s41379-019-0358-x_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cjp2.18","article-title":"In-depth molecular profiling of the biphasic components of uterine carcinosarcomas","volume":"1","author":"McConechy","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"10.1038\/s41379-019-0358-x_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/107327481602300111","article-title":"Genetic investigation of uterine carcinosarcoma: case report and cohort analysis","volume":"23","author":"Hembree","year":"2016","journal-title":"Cancer Control"},{"key":"10.1038\/s41379-019-0358-x_bib29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2010.11.039","article-title":"Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin","volume":"121","author":"Growdon","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1038\/s41379-019-0358-x_bib31","doi-asserted-by":"crossref","first-page":"12238","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41379-019-0358-x_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ygyno.2004.07.041","article-title":"ERBB-2 gene overexpression and amplification in uterine sarcomas","volume":"95","author":"Amant","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00428-007-0557-6","article-title":"Molecular genetic aberrations of ovarian and uterine carcinosarcomas\u2014a CGH and FISH study","volume":"452","author":"Schipf","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1038\/s41379-019-0358-x_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2004.09.050","article-title":"COX-2, c-KIT and HER-2\/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?","volume":"96","author":"Raspollini","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2006.11.001","article-title":"Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets","volume":"105","author":"Cimbaluk","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1349-7006.2003.tb01389.x","article-title":"Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma","volume":"94","author":"Sawada","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1038\/s41379-019-0358-x_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/PGP.0b013e31827fedef","article-title":"AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma","volume":"32","author":"Saglam","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"10.1038\/s41379-019-0358-x_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-019-0358-x_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13000-016-0553-8","article-title":"Systematic assessment of HER2\/neu in gynecologic neoplasms, an institutional experience","volume":"11","author":"Woo","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1038\/s41379-019-0358-x_bib41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/modpathol.2008.108","article-title":"Immunophenotyping of serous carcinoma of the female genital tract","volume":"21","author":"Nofech-Mozes","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0358-x_bib42","first-page":"635","article-title":"Expression of HER2\/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary","volume":"14","author":"Karaferic","year":"2009","journal-title":"J BUON"},{"key":"10.1038\/s41379-019-0358-x_bib43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-019-0358-x_bib44","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"Ruschoff","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-019-0358-x_bib45","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1038\/s41379-019-0358-x_bib46","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/s41379-019-0358-x_bib47","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-019-0358-x_bib48","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br J Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0358-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222009516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222009516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-019-0358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:43:31Z","timestamp":1760229811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222009516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0893395222009516"],"URL":"https:\/\/doi.org\/10.1038\/s41379-019-0358-x","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-019-0358-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}